nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCG2—Ezetimibe—atherosclerosis	0.0461	0.0643	CbGbCtD
Buprenorphine—ABCG2—Rosuvastatin—atherosclerosis	0.0461	0.0643	CbGbCtD
Buprenorphine—ABCG2—Pravastatin—atherosclerosis	0.0419	0.0585	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0316	0.0442	CbGbCtD
Buprenorphine—CYP3A7—Simvastatin—atherosclerosis	0.0316	0.0442	CbGbCtD
Buprenorphine—CYP3A7—Lovastatin—atherosclerosis	0.031	0.0432	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.031	0.0432	CbGbCtD
Buprenorphine—CYP3A5—Rosuvastatin—atherosclerosis	0.0255	0.0356	CbGbCtD
Buprenorphine—CYP3A5—Simvastatin—atherosclerosis	0.0237	0.0331	CbGbCtD
Buprenorphine—CYP3A5—Pravastatin—atherosclerosis	0.0232	0.0324	CbGbCtD
Buprenorphine—CYP3A5—Lovastatin—atherosclerosis	0.0232	0.0324	CbGbCtD
Buprenorphine—CYP2C8—Simvastatin—atherosclerosis	0.0228	0.0319	CbGbCtD
Buprenorphine—CYP2C8—Pravastatin—atherosclerosis	0.0223	0.0312	CbGbCtD
Buprenorphine—CYP2C8—Lovastatin—atherosclerosis	0.0223	0.0312	CbGbCtD
Buprenorphine—CYP2C19—Rosuvastatin—atherosclerosis	0.0206	0.0288	CbGbCtD
Buprenorphine—CYP2C19—Simvastatin—atherosclerosis	0.0191	0.0267	CbGbCtD
Buprenorphine—CYP2C19—Lovastatin—atherosclerosis	0.0187	0.0262	CbGbCtD
Buprenorphine—CYP2D6—Niacin—atherosclerosis	0.0184	0.0257	CbGbCtD
Buprenorphine—CYP2C9—Rosuvastatin—atherosclerosis	0.0171	0.0239	CbGbCtD
Buprenorphine—ABCB1—Ezetimibe—atherosclerosis	0.0166	0.0232	CbGbCtD
Buprenorphine—CYP2C9—Simvastatin—atherosclerosis	0.0159	0.0222	CbGbCtD
Buprenorphine—CYP2C9—Pravastatin—atherosclerosis	0.0156	0.0217	CbGbCtD
Buprenorphine—CYP2C9—Lovastatin—atherosclerosis	0.0156	0.0217	CbGbCtD
Buprenorphine—ABCB1—Simvastatin—atherosclerosis	0.0154	0.0216	CbGbCtD
Buprenorphine—ABCB1—Pravastatin—atherosclerosis	0.0151	0.0211	CbGbCtD
Buprenorphine—ABCB1—Lovastatin—atherosclerosis	0.0151	0.0211	CbGbCtD
Buprenorphine—CYP2D6—Simvastatin—atherosclerosis	0.0146	0.0203	CbGbCtD
Buprenorphine—CYP2D6—Pravastatin—atherosclerosis	0.0142	0.0199	CbGbCtD
Buprenorphine—CYP2D6—Lovastatin—atherosclerosis	0.0142	0.0199	CbGbCtD
Buprenorphine—CYP3A4—Rosuvastatin—atherosclerosis	0.00996	0.0139	CbGbCtD
Buprenorphine—CYP3A4—Ezetimibe—atherosclerosis	0.00996	0.0139	CbGbCtD
Buprenorphine—CYP3A4—Simvastatin—atherosclerosis	0.00926	0.0129	CbGbCtD
Buprenorphine—CYP3A4—Pravastatin—atherosclerosis	0.00906	0.0126	CbGbCtD
Buprenorphine—CYP3A4—Lovastatin—atherosclerosis	0.00906	0.0126	CbGbCtD
Buprenorphine—Naloxone—TLR4—atherosclerosis	0.00232	0.712	CrCbGaD
Buprenorphine—Naloxone—ESR1—atherosclerosis	0.000651	0.2	CrCbGaD
Buprenorphine—Visual impairment—Pravastatin—atherosclerosis	0.000383	0.00228	CcSEcCtD
Buprenorphine—Erythema—Simvastatin—atherosclerosis	0.000382	0.00228	CcSEcCtD
Buprenorphine—Ill-defined disorder—Lovastatin—atherosclerosis	0.000379	0.00226	CcSEcCtD
Buprenorphine—Eye disorder—Niacin—atherosclerosis	0.000377	0.00225	CcSEcCtD
Buprenorphine—Flatulence—Simvastatin—atherosclerosis	0.000377	0.00224	CcSEcCtD
Buprenorphine—Tinnitus—Niacin—atherosclerosis	0.000376	0.00224	CcSEcCtD
Buprenorphine—Dysgeusia—Simvastatin—atherosclerosis	0.000374	0.00223	CcSEcCtD
Buprenorphine—Flushing—Niacin—atherosclerosis	0.000374	0.00223	CcSEcCtD
Buprenorphine—Angioedema—Lovastatin—atherosclerosis	0.000374	0.00223	CcSEcCtD
Buprenorphine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000372	0.00222	CcSEcCtD
Buprenorphine—Tinnitus—Pravastatin—atherosclerosis	0.00037	0.00221	CcSEcCtD
Buprenorphine—Malaise—Lovastatin—atherosclerosis	0.000369	0.0022	CcSEcCtD
Buprenorphine—Flushing—Pravastatin—atherosclerosis	0.000369	0.0022	CcSEcCtD
Buprenorphine—Cardiac disorder—Pravastatin—atherosclerosis	0.000369	0.0022	CcSEcCtD
Buprenorphine—Muscle spasms—Simvastatin—atherosclerosis	0.000368	0.00219	CcSEcCtD
Buprenorphine—Vertigo—Lovastatin—atherosclerosis	0.000367	0.00219	CcSEcCtD
Buprenorphine—Angioedema—Ezetimibe—atherosclerosis	0.000366	0.00218	CcSEcCtD
Buprenorphine—Angiopathy—Niacin—atherosclerosis	0.000366	0.00218	CcSEcCtD
Buprenorphine—Chills—Niacin—atherosclerosis	0.000362	0.00216	CcSEcCtD
Buprenorphine—Malaise—Ezetimibe—atherosclerosis	0.000362	0.00215	CcSEcCtD
Buprenorphine—Vision blurred—Simvastatin—atherosclerosis	0.00036	0.00215	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000359	0.00214	CcSEcCtD
Buprenorphine—Tremor—Simvastatin—atherosclerosis	0.000358	0.00213	CcSEcCtD
Buprenorphine—Chills—Pravastatin—atherosclerosis	0.000356	0.00212	CcSEcCtD
Buprenorphine—Insomnia—Rosuvastatin—atherosclerosis	0.000356	0.00212	CcSEcCtD
Buprenorphine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000355	0.00211	CcSEcCtD
Buprenorphine—Palpitations—Ezetimibe—atherosclerosis	0.000354	0.00211	CcSEcCtD
Buprenorphine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000354	0.00211	CcSEcCtD
Buprenorphine—Malnutrition—Niacin—atherosclerosis	0.000351	0.00209	CcSEcCtD
Buprenorphine—Erythema—Niacin—atherosclerosis	0.000351	0.00209	CcSEcCtD
Buprenorphine—Cough—Ezetimibe—atherosclerosis	0.00035	0.00208	CcSEcCtD
Buprenorphine—Angioedema—Simvastatin—atherosclerosis	0.000349	0.00208	CcSEcCtD
Buprenorphine—Chest pain—Lovastatin—atherosclerosis	0.000348	0.00207	CcSEcCtD
Buprenorphine—Myalgia—Lovastatin—atherosclerosis	0.000348	0.00207	CcSEcCtD
Buprenorphine—Arthralgia—Lovastatin—atherosclerosis	0.000348	0.00207	CcSEcCtD
Buprenorphine—Anxiety—Lovastatin—atherosclerosis	0.000347	0.00207	CcSEcCtD
Buprenorphine—Dyspepsia—Rosuvastatin—atherosclerosis	0.000347	0.00206	CcSEcCtD
Buprenorphine—Hypertension—Ezetimibe—atherosclerosis	0.000346	0.00206	CcSEcCtD
Buprenorphine—Flatulence—Niacin—atherosclerosis	0.000346	0.00206	CcSEcCtD
Buprenorphine—Malaise—Simvastatin—atherosclerosis	0.000345	0.00205	CcSEcCtD
Buprenorphine—Tension—Niacin—atherosclerosis	0.000345	0.00205	CcSEcCtD
Buprenorphine—Discomfort—Lovastatin—atherosclerosis	0.000344	0.00205	CcSEcCtD
Buprenorphine—Vertigo—Simvastatin—atherosclerosis	0.000344	0.00205	CcSEcCtD
Buprenorphine—Myalgia—Ezetimibe—atherosclerosis	0.000341	0.00203	CcSEcCtD
Buprenorphine—Arthralgia—Ezetimibe—atherosclerosis	0.000341	0.00203	CcSEcCtD
Buprenorphine—Chest pain—Ezetimibe—atherosclerosis	0.000341	0.00203	CcSEcCtD
Buprenorphine—Nervousness—Niacin—atherosclerosis	0.000341	0.00203	CcSEcCtD
Buprenorphine—Flatulence—Pravastatin—atherosclerosis	0.000341	0.00203	CcSEcCtD
Buprenorphine—Dry mouth—Lovastatin—atherosclerosis	0.00034	0.00203	CcSEcCtD
Buprenorphine—Tension—Pravastatin—atherosclerosis	0.000339	0.00202	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000339	0.00202	CcSEcCtD
Buprenorphine—Dysgeusia—Pravastatin—atherosclerosis	0.000339	0.00202	CcSEcCtD
Buprenorphine—Muscle spasms—Niacin—atherosclerosis	0.000338	0.00201	CcSEcCtD
Buprenorphine—Discomfort—Ezetimibe—atherosclerosis	0.000337	0.00201	CcSEcCtD
Buprenorphine—Pain—Rosuvastatin—atherosclerosis	0.000337	0.00201	CcSEcCtD
Buprenorphine—Constipation—Rosuvastatin—atherosclerosis	0.000337	0.00201	CcSEcCtD
Buprenorphine—Confusional state—Lovastatin—atherosclerosis	0.000336	0.002	CcSEcCtD
Buprenorphine—Nervousness—Pravastatin—atherosclerosis	0.000336	0.002	CcSEcCtD
Buprenorphine—Dry mouth—Ezetimibe—atherosclerosis	0.000334	0.00199	CcSEcCtD
Buprenorphine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000334	0.00199	CcSEcCtD
Buprenorphine—Muscle spasms—Pravastatin—atherosclerosis	0.000332	0.00198	CcSEcCtD
Buprenorphine—Infection—Lovastatin—atherosclerosis	0.000331	0.00197	CcSEcCtD
Buprenorphine—Vision blurred—Niacin—atherosclerosis	0.000331	0.00197	CcSEcCtD
Buprenorphine—Confusional state—Ezetimibe—atherosclerosis	0.00033	0.00197	CcSEcCtD
Buprenorphine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000327	0.00195	CcSEcCtD
Buprenorphine—Vision blurred—Pravastatin—atherosclerosis	0.000326	0.00194	CcSEcCtD
Buprenorphine—Arthralgia—Simvastatin—atherosclerosis	0.000326	0.00194	CcSEcCtD
Buprenorphine—Myalgia—Simvastatin—atherosclerosis	0.000326	0.00194	CcSEcCtD
Buprenorphine—Chest pain—Simvastatin—atherosclerosis	0.000326	0.00194	CcSEcCtD
Buprenorphine—Infection—Ezetimibe—atherosclerosis	0.000325	0.00194	CcSEcCtD
Buprenorphine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000324	0.00193	CcSEcCtD
Buprenorphine—Anxiety—Simvastatin—atherosclerosis	0.000324	0.00193	CcSEcCtD
Buprenorphine—Tremor—Pravastatin—atherosclerosis	0.000324	0.00193	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000322	0.00192	CcSEcCtD
Buprenorphine—Discomfort—Simvastatin—atherosclerosis	0.000322	0.00192	CcSEcCtD
Buprenorphine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000321	0.00191	CcSEcCtD
Buprenorphine—Angioedema—Niacin—atherosclerosis	0.000321	0.00191	CcSEcCtD
Buprenorphine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000321	0.00191	CcSEcCtD
Buprenorphine—Anorexia—Lovastatin—atherosclerosis	0.000318	0.00189	CcSEcCtD
Buprenorphine—Skin disorder—Ezetimibe—atherosclerosis	0.000318	0.00189	CcSEcCtD
Buprenorphine—Angioedema—Pravastatin—atherosclerosis	0.000316	0.00188	CcSEcCtD
Buprenorphine—Vertigo—Niacin—atherosclerosis	0.000315	0.00188	CcSEcCtD
Buprenorphine—Syncope—Niacin—atherosclerosis	0.000315	0.00188	CcSEcCtD
Buprenorphine—Confusional state—Simvastatin—atherosclerosis	0.000315	0.00187	CcSEcCtD
Buprenorphine—Urticaria—Rosuvastatin—atherosclerosis	0.000313	0.00186	CcSEcCtD
Buprenorphine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000312	0.00186	CcSEcCtD
Buprenorphine—Oedema—Simvastatin—atherosclerosis	0.000312	0.00186	CcSEcCtD
Buprenorphine—Malaise—Pravastatin—atherosclerosis	0.000312	0.00186	CcSEcCtD
Buprenorphine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000311	0.00185	CcSEcCtD
Buprenorphine—Vertigo—Pravastatin—atherosclerosis	0.000311	0.00185	CcSEcCtD
Buprenorphine—Palpitations—Niacin—atherosclerosis	0.00031	0.00185	CcSEcCtD
Buprenorphine—Infection—Simvastatin—atherosclerosis	0.00031	0.00185	CcSEcCtD
Buprenorphine—Loss of consciousness—Niacin—atherosclerosis	0.000309	0.00184	CcSEcCtD
Buprenorphine—Cough—Niacin—atherosclerosis	0.000306	0.00183	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000304	0.00181	CcSEcCtD
Buprenorphine—Insomnia—Lovastatin—atherosclerosis	0.000302	0.0018	CcSEcCtD
Buprenorphine—Cough—Pravastatin—atherosclerosis	0.000302	0.0018	CcSEcCtD
Buprenorphine—Paraesthesia—Lovastatin—atherosclerosis	0.0003	0.00178	CcSEcCtD
Buprenorphine—Myalgia—Niacin—atherosclerosis	0.000299	0.00178	CcSEcCtD
Buprenorphine—Arthralgia—Niacin—atherosclerosis	0.000299	0.00178	CcSEcCtD
Buprenorphine—Hypertension—Pravastatin—atherosclerosis	0.000298	0.00178	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000298	0.00178	CcSEcCtD
Buprenorphine—Anorexia—Simvastatin—atherosclerosis	0.000298	0.00177	CcSEcCtD
Buprenorphine—Dyspnoea—Lovastatin—atherosclerosis	0.000297	0.00177	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000297	0.00177	CcSEcCtD
Buprenorphine—Insomnia—Ezetimibe—atherosclerosis	0.000296	0.00176	CcSEcCtD
Buprenorphine—Myalgia—Pravastatin—atherosclerosis	0.000294	0.00175	CcSEcCtD
Buprenorphine—Chest pain—Pravastatin—atherosclerosis	0.000294	0.00175	CcSEcCtD
Buprenorphine—Arthralgia—Pravastatin—atherosclerosis	0.000294	0.00175	CcSEcCtD
Buprenorphine—Paraesthesia—Ezetimibe—atherosclerosis	0.000294	0.00175	CcSEcCtD
Buprenorphine—Dyspepsia—Lovastatin—atherosclerosis	0.000294	0.00175	CcSEcCtD
Buprenorphine—Anxiety—Pravastatin—atherosclerosis	0.000293	0.00175	CcSEcCtD
Buprenorphine—Dry mouth—Niacin—atherosclerosis	0.000292	0.00174	CcSEcCtD
Buprenorphine—Dyspnoea—Ezetimibe—atherosclerosis	0.000292	0.00174	CcSEcCtD
Buprenorphine—Discomfort—Pravastatin—atherosclerosis	0.000291	0.00173	CcSEcCtD
Buprenorphine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00029	0.00173	CcSEcCtD
Buprenorphine—Decreased appetite—Lovastatin—atherosclerosis	0.00029	0.00173	CcSEcCtD
Buprenorphine—Naloxone—ALB—atherosclerosis	0.00029	0.0888	CrCbGaD
Buprenorphine—Dyspepsia—Ezetimibe—atherosclerosis	0.000288	0.00172	CcSEcCtD
Buprenorphine—Fatigue—Lovastatin—atherosclerosis	0.000288	0.00171	CcSEcCtD
Buprenorphine—Anaphylactic shock—Niacin—atherosclerosis	0.000287	0.00171	CcSEcCtD
Buprenorphine—Oedema—Niacin—atherosclerosis	0.000287	0.00171	CcSEcCtD
Buprenorphine—Constipation—Lovastatin—atherosclerosis	0.000285	0.0017	CcSEcCtD
Buprenorphine—Pain—Lovastatin—atherosclerosis	0.000285	0.0017	CcSEcCtD
Buprenorphine—Confusional state—Pravastatin—atherosclerosis	0.000285	0.00169	CcSEcCtD
Buprenorphine—Decreased appetite—Ezetimibe—atherosclerosis	0.000284	0.00169	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000284	0.00169	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000283	0.00168	CcSEcCtD
Buprenorphine—Asthenia—Rosuvastatin—atherosclerosis	0.000282	0.00168	CcSEcCtD
Buprenorphine—Insomnia—Simvastatin—atherosclerosis	0.000282	0.00168	CcSEcCtD
Buprenorphine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000282	0.00168	CcSEcCtD
Buprenorphine—Oedema—Pravastatin—atherosclerosis	0.000282	0.00168	CcSEcCtD
Buprenorphine—Fatigue—Ezetimibe—atherosclerosis	0.000282	0.00168	CcSEcCtD
Buprenorphine—Shock—Niacin—atherosclerosis	0.000282	0.00168	CcSEcCtD
Buprenorphine—Infection—Pravastatin—atherosclerosis	0.00028	0.00167	CcSEcCtD
Buprenorphine—Paraesthesia—Simvastatin—atherosclerosis	0.00028	0.00167	CcSEcCtD
Buprenorphine—Constipation—Ezetimibe—atherosclerosis	0.00028	0.00167	CcSEcCtD
Buprenorphine—Pain—Ezetimibe—atherosclerosis	0.00028	0.00167	CcSEcCtD
Buprenorphine—Tachycardia—Niacin—atherosclerosis	0.00028	0.00167	CcSEcCtD
Buprenorphine—Pruritus—Rosuvastatin—atherosclerosis	0.000279	0.00166	CcSEcCtD
Buprenorphine—Skin disorder—Niacin—atherosclerosis	0.000278	0.00166	CcSEcCtD
Buprenorphine—Dyspnoea—Simvastatin—atherosclerosis	0.000278	0.00166	CcSEcCtD
Buprenorphine—Hyperhidrosis—Niacin—atherosclerosis	0.000277	0.00165	CcSEcCtD
Buprenorphine—Feeling abnormal—Lovastatin—atherosclerosis	0.000275	0.00164	CcSEcCtD
Buprenorphine—Dyspepsia—Simvastatin—atherosclerosis	0.000275	0.00164	CcSEcCtD
Buprenorphine—Anorexia—Niacin—atherosclerosis	0.000273	0.00163	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000273	0.00163	CcSEcCtD
Buprenorphine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000273	0.00162	CcSEcCtD
Buprenorphine—Decreased appetite—Simvastatin—atherosclerosis	0.000271	0.00162	CcSEcCtD
Buprenorphine—Feeling abnormal—Ezetimibe—atherosclerosis	0.00027	0.00161	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000269	0.00161	CcSEcCtD
Buprenorphine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000269	0.0016	CcSEcCtD
Buprenorphine—Fatigue—Simvastatin—atherosclerosis	0.000269	0.0016	CcSEcCtD
Buprenorphine—Anorexia—Pravastatin—atherosclerosis	0.000269	0.0016	CcSEcCtD
Buprenorphine—Hypotension—Niacin—atherosclerosis	0.000268	0.0016	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000268	0.00159	CcSEcCtD
Buprenorphine—Pain—Simvastatin—atherosclerosis	0.000267	0.00159	CcSEcCtD
Buprenorphine—Constipation—Simvastatin—atherosclerosis	0.000267	0.00159	CcSEcCtD
Buprenorphine—Urticaria—Lovastatin—atherosclerosis	0.000265	0.00158	CcSEcCtD
Buprenorphine—Abdominal pain—Lovastatin—atherosclerosis	0.000264	0.00157	CcSEcCtD
Buprenorphine—Body temperature increased—Lovastatin—atherosclerosis	0.000264	0.00157	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000261	0.00156	CcSEcCtD
Buprenorphine—Dizziness—Rosuvastatin—atherosclerosis	0.00026	0.00155	CcSEcCtD
Buprenorphine—Urticaria—Ezetimibe—atherosclerosis	0.00026	0.00155	CcSEcCtD
Buprenorphine—Insomnia—Niacin—atherosclerosis	0.000259	0.00154	CcSEcCtD
Buprenorphine—Abdominal pain—Ezetimibe—atherosclerosis	0.000259	0.00154	CcSEcCtD
Buprenorphine—Body temperature increased—Ezetimibe—atherosclerosis	0.000259	0.00154	CcSEcCtD
Buprenorphine—Paraesthesia—Niacin—atherosclerosis	0.000257	0.00153	CcSEcCtD
Buprenorphine—Feeling abnormal—Simvastatin—atherosclerosis	0.000257	0.00153	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000257	0.00153	CcSEcCtD
Buprenorphine—Dyspnoea—Niacin—atherosclerosis	0.000255	0.00152	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000255	0.00152	CcSEcCtD
Buprenorphine—Insomnia—Pravastatin—atherosclerosis	0.000255	0.00152	CcSEcCtD
Buprenorphine—Somnolence—Niacin—atherosclerosis	0.000255	0.00152	CcSEcCtD
Buprenorphine—Paraesthesia—Pravastatin—atherosclerosis	0.000253	0.00151	CcSEcCtD
Buprenorphine—Dyspepsia—Niacin—atherosclerosis	0.000252	0.0015	CcSEcCtD
Buprenorphine—Dyspnoea—Pravastatin—atherosclerosis	0.000252	0.0015	CcSEcCtD
Buprenorphine—Decreased appetite—Niacin—atherosclerosis	0.000249	0.00148	CcSEcCtD
Buprenorphine—Dyspepsia—Pravastatin—atherosclerosis	0.000248	0.00148	CcSEcCtD
Buprenorphine—Rash—Rosuvastatin—atherosclerosis	0.000248	0.00148	CcSEcCtD
Buprenorphine—Dermatitis—Rosuvastatin—atherosclerosis	0.000248	0.00148	CcSEcCtD
Buprenorphine—Urticaria—Simvastatin—atherosclerosis	0.000248	0.00148	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000247	0.00147	CcSEcCtD
Buprenorphine—Body temperature increased—Simvastatin—atherosclerosis	0.000247	0.00147	CcSEcCtD
Buprenorphine—Abdominal pain—Simvastatin—atherosclerosis	0.000247	0.00147	CcSEcCtD
Buprenorphine—Headache—Rosuvastatin—atherosclerosis	0.000247	0.00147	CcSEcCtD
Buprenorphine—Hypersensitivity—Lovastatin—atherosclerosis	0.000246	0.00146	CcSEcCtD
Buprenorphine—Decreased appetite—Pravastatin—atherosclerosis	0.000245	0.00146	CcSEcCtD
Buprenorphine—Pain—Niacin—atherosclerosis	0.000245	0.00146	CcSEcCtD
Buprenorphine—Fatigue—Pravastatin—atherosclerosis	0.000243	0.00145	CcSEcCtD
Buprenorphine—Pain—Pravastatin—atherosclerosis	0.000241	0.00144	CcSEcCtD
Buprenorphine—Constipation—Pravastatin—atherosclerosis	0.000241	0.00144	CcSEcCtD
Buprenorphine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000241	0.00144	CcSEcCtD
Buprenorphine—Asthenia—Lovastatin—atherosclerosis	0.000239	0.00143	CcSEcCtD
Buprenorphine—Pruritus—Lovastatin—atherosclerosis	0.000236	0.00141	CcSEcCtD
Buprenorphine—Asthenia—Ezetimibe—atherosclerosis	0.000235	0.0014	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Niacin—atherosclerosis	0.000234	0.0014	CcSEcCtD
Buprenorphine—Nausea—Rosuvastatin—atherosclerosis	0.000234	0.00139	CcSEcCtD
Buprenorphine—Feeling abnormal—Pravastatin—atherosclerosis	0.000233	0.00139	CcSEcCtD
Buprenorphine—Pruritus—Ezetimibe—atherosclerosis	0.000232	0.00138	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000231	0.00137	CcSEcCtD
Buprenorphine—Hypersensitivity—Simvastatin—atherosclerosis	0.00023	0.00137	CcSEcCtD
Buprenorphine—Diarrhoea—Lovastatin—atherosclerosis	0.000228	0.00136	CcSEcCtD
Buprenorphine—Urticaria—Niacin—atherosclerosis	0.000228	0.00136	CcSEcCtD
Buprenorphine—Body temperature increased—Niacin—atherosclerosis	0.000227	0.00135	CcSEcCtD
Buprenorphine—Abdominal pain—Niacin—atherosclerosis	0.000227	0.00135	CcSEcCtD
Buprenorphine—Urticaria—Pravastatin—atherosclerosis	0.000224	0.00134	CcSEcCtD
Buprenorphine—Asthenia—Simvastatin—atherosclerosis	0.000224	0.00133	CcSEcCtD
Buprenorphine—Diarrhoea—Ezetimibe—atherosclerosis	0.000224	0.00133	CcSEcCtD
Buprenorphine—Abdominal pain—Pravastatin—atherosclerosis	0.000223	0.00133	CcSEcCtD
Buprenorphine—Body temperature increased—Pravastatin—atherosclerosis	0.000223	0.00133	CcSEcCtD
Buprenorphine—Pruritus—Simvastatin—atherosclerosis	0.000221	0.00132	CcSEcCtD
Buprenorphine—Dizziness—Lovastatin—atherosclerosis	0.000221	0.00131	CcSEcCtD
Buprenorphine—Dizziness—Ezetimibe—atherosclerosis	0.000216	0.00129	CcSEcCtD
Buprenorphine—Diarrhoea—Simvastatin—atherosclerosis	0.000214	0.00127	CcSEcCtD
Buprenorphine—Vomiting—Lovastatin—atherosclerosis	0.000212	0.00126	CcSEcCtD
Buprenorphine—Hypersensitivity—Niacin—atherosclerosis	0.000211	0.00126	CcSEcCtD
Buprenorphine—Rash—Lovastatin—atherosclerosis	0.00021	0.00125	CcSEcCtD
Buprenorphine—Dermatitis—Lovastatin—atherosclerosis	0.00021	0.00125	CcSEcCtD
Buprenorphine—Headache—Lovastatin—atherosclerosis	0.000209	0.00125	CcSEcCtD
Buprenorphine—Vomiting—Ezetimibe—atherosclerosis	0.000208	0.00124	CcSEcCtD
Buprenorphine—Hypersensitivity—Pravastatin—atherosclerosis	0.000208	0.00124	CcSEcCtD
Buprenorphine—Dizziness—Simvastatin—atherosclerosis	0.000206	0.00123	CcSEcCtD
Buprenorphine—Rash—Ezetimibe—atherosclerosis	0.000206	0.00123	CcSEcCtD
Buprenorphine—Dermatitis—Ezetimibe—atherosclerosis	0.000206	0.00123	CcSEcCtD
Buprenorphine—Asthenia—Niacin—atherosclerosis	0.000206	0.00122	CcSEcCtD
Buprenorphine—Headache—Ezetimibe—atherosclerosis	0.000205	0.00122	CcSEcCtD
Buprenorphine—Pruritus—Niacin—atherosclerosis	0.000203	0.00121	CcSEcCtD
Buprenorphine—Asthenia—Pravastatin—atherosclerosis	0.000202	0.00121	CcSEcCtD
Buprenorphine—Pruritus—Pravastatin—atherosclerosis	0.0002	0.00119	CcSEcCtD
Buprenorphine—Vomiting—Simvastatin—atherosclerosis	0.000198	0.00118	CcSEcCtD
Buprenorphine—Nausea—Lovastatin—atherosclerosis	0.000198	0.00118	CcSEcCtD
Buprenorphine—Rash—Simvastatin—atherosclerosis	0.000197	0.00117	CcSEcCtD
Buprenorphine—Dermatitis—Simvastatin—atherosclerosis	0.000197	0.00117	CcSEcCtD
Buprenorphine—Diarrhoea—Niacin—atherosclerosis	0.000196	0.00117	CcSEcCtD
Buprenorphine—Headache—Simvastatin—atherosclerosis	0.000196	0.00116	CcSEcCtD
Buprenorphine—Nausea—Ezetimibe—atherosclerosis	0.000194	0.00116	CcSEcCtD
Buprenorphine—Diarrhoea—Pravastatin—atherosclerosis	0.000193	0.00115	CcSEcCtD
Buprenorphine—Dizziness—Niacin—atherosclerosis	0.00019	0.00113	CcSEcCtD
Buprenorphine—Dizziness—Pravastatin—atherosclerosis	0.000187	0.00111	CcSEcCtD
Buprenorphine—Nausea—Simvastatin—atherosclerosis	0.000185	0.0011	CcSEcCtD
Buprenorphine—Vomiting—Niacin—atherosclerosis	0.000182	0.00109	CcSEcCtD
Buprenorphine—Rash—Niacin—atherosclerosis	0.000181	0.00108	CcSEcCtD
Buprenorphine—Dermatitis—Niacin—atherosclerosis	0.000181	0.00108	CcSEcCtD
Buprenorphine—Headache—Niacin—atherosclerosis	0.00018	0.00107	CcSEcCtD
Buprenorphine—Vomiting—Pravastatin—atherosclerosis	0.000179	0.00107	CcSEcCtD
Buprenorphine—Rash—Pravastatin—atherosclerosis	0.000178	0.00106	CcSEcCtD
Buprenorphine—Dermatitis—Pravastatin—atherosclerosis	0.000178	0.00106	CcSEcCtD
Buprenorphine—Headache—Pravastatin—atherosclerosis	0.000177	0.00105	CcSEcCtD
Buprenorphine—Nausea—Niacin—atherosclerosis	0.00017	0.00101	CcSEcCtD
Buprenorphine—Nausea—Pravastatin—atherosclerosis	0.000168	0.000998	CcSEcCtD
Buprenorphine—CYP2C9—Metabolism—HMGCR—atherosclerosis	6.73e-06	5.98e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	6.71e-06	5.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOA2—atherosclerosis	6.71e-06	5.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALOX15—atherosclerosis	6.71e-06	5.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	6.71e-06	5.96e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—LPL—atherosclerosis	6.67e-06	5.93e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—INS—atherosclerosis	6.67e-06	5.93e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NOS3—atherosclerosis	6.67e-06	5.93e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.65e-06	5.91e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NAMPT—atherosclerosis	6.63e-06	5.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCG5—atherosclerosis	6.63e-06	5.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—INS—atherosclerosis	6.61e-06	5.87e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	6.59e-06	5.86e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—LIPC—atherosclerosis	6.59e-06	5.85e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ABCA1—atherosclerosis	6.58e-06	5.84e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOC3—atherosclerosis	6.55e-06	5.82e-05	CbGpPWpGaD
Buprenorphine—OPRD1—GPCR downstream signaling—AKT1—atherosclerosis	6.52e-06	5.79e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GPX1—atherosclerosis	6.51e-06	5.78e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—LDLR—atherosclerosis	6.51e-06	5.78e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—MAPK3—atherosclerosis	6.5e-06	5.78e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—INS—atherosclerosis	6.43e-06	5.71e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ABCA1—atherosclerosis	6.42e-06	5.7e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—IL6—atherosclerosis	6.42e-06	5.7e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CG—atherosclerosis	6.4e-06	5.69e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LPA—atherosclerosis	6.4e-06	5.69e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CETP—atherosclerosis	6.36e-06	5.65e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CD36—atherosclerosis	6.34e-06	5.63e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCL2—atherosclerosis	6.32e-06	5.62e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—HMOX1—atherosclerosis	6.32e-06	5.61e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—atherosclerosis	6.31e-06	5.6e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IGF1—atherosclerosis	6.22e-06	5.52e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—BGN—atherosclerosis	6.2e-06	5.51e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARG—atherosclerosis	6.18e-06	5.49e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOA5—atherosclerosis	6.14e-06	5.45e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—ALB—atherosclerosis	6.12e-06	5.43e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—atherosclerosis	6.1e-06	5.42e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—SCARB1—atherosclerosis	6.09e-06	5.41e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.07e-06	5.39e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ALB—atherosclerosis	6.06e-06	5.38e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—INS—atherosclerosis	6.06e-06	5.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOB—atherosclerosis	6.05e-06	5.38e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ABCA1—atherosclerosis	6.05e-06	5.37e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—NFKB1—atherosclerosis	6.04e-06	5.36e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—MTHFR—atherosclerosis	6.01e-06	5.34e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ABCA1—atherosclerosis	6e-06	5.33e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK8—atherosclerosis	5.94e-06	5.27e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	5.93e-06	5.26e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—AKT1—atherosclerosis	5.92e-06	5.26e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—atherosclerosis	5.92e-06	5.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	5.91e-06	5.25e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SERPINE1—atherosclerosis	5.9e-06	5.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARA—atherosclerosis	5.9e-06	5.24e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTM1—atherosclerosis	5.89e-06	5.23e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—NOS3—atherosclerosis	5.85e-06	5.2e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—NOS3—atherosclerosis	5.8e-06	5.15e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—LPL—atherosclerosis	5.78e-06	5.14e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HMGCR—atherosclerosis	5.75e-06	5.11e-05	CbGpPWpGaD
Buprenorphine—OPRK1—GPCR downstream signaling—AKT1—atherosclerosis	5.72e-06	5.08e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AGT—atherosclerosis	5.71e-06	5.07e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALOX5—atherosclerosis	5.7e-06	5.07e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HMOX1—atherosclerosis	5.64e-06	5.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GPX1—atherosclerosis	5.64e-06	5.01e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NOS3—atherosclerosis	5.64e-06	5.01e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—IL6—atherosclerosis	5.63e-06	5e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOE—atherosclerosis	5.59e-06	4.97e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ALB—atherosclerosis	5.56e-06	4.94e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CAV1—atherosclerosis	5.54e-06	4.92e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—APOA1—atherosclerosis	5.53e-06	4.91e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HMOX1—atherosclerosis	5.51e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CD36—atherosclerosis	5.49e-06	4.88e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—VEGFA—atherosclerosis	5.48e-06	4.87e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—STAT3—atherosclerosis	5.43e-06	4.82e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOB—atherosclerosis	5.4e-06	4.8e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—atherosclerosis	5.35e-06	4.75e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—atherosclerosis	5.35e-06	4.75e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NOS3—atherosclerosis	5.31e-06	4.72e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—atherosclerosis	5.3e-06	4.71e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—NFKB1—atherosclerosis	5.29e-06	4.7e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOB—atherosclerosis	5.27e-06	4.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—atherosclerosis	5.26e-06	4.67e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MTHFR—atherosclerosis	5.2e-06	4.62e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK8—atherosclerosis	5.2e-06	4.62e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—atherosclerosis	5.19e-06	4.61e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HMOX1—atherosclerosis	5.19e-06	4.61e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.18e-06	4.61e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MAPK3—atherosclerosis	5.18e-06	4.61e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—LPL—atherosclerosis	5.16e-06	4.58e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HMOX1—atherosclerosis	5.14e-06	4.57e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—atherosclerosis	5.13e-06	4.56e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ABCA1—atherosclerosis	5.12e-06	4.55e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.12e-06	4.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARA—atherosclerosis	5.11e-06	4.54e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LIPC—atherosclerosis	5.08e-06	4.52e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOC3—atherosclerosis	5.05e-06	4.49e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—atherosclerosis	5.05e-06	4.49e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—LPL—atherosclerosis	5.04e-06	4.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GPX1—atherosclerosis	5.03e-06	4.47e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFB1—atherosclerosis	5.03e-06	4.47e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LDLR—atherosclerosis	5.02e-06	4.46e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—atherosclerosis	5e-06	4.44e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOB—atherosclerosis	4.97e-06	4.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AGT—atherosclerosis	4.95e-06	4.39e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOB—atherosclerosis	4.93e-06	4.38e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GPX1—atherosclerosis	4.91e-06	4.36e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CETP—atherosclerosis	4.91e-06	4.36e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CD36—atherosclerosis	4.9e-06	4.36e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—atherosclerosis	4.87e-06	4.33e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—atherosclerosis	4.86e-06	4.32e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOE—atherosclerosis	4.85e-06	4.3e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—atherosclerosis	4.83e-06	4.3e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—atherosclerosis	4.83e-06	4.29e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—atherosclerosis	4.81e-06	4.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CAV1—atherosclerosis	4.8e-06	4.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—atherosclerosis	4.79e-06	4.26e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—APOA1—atherosclerosis	4.79e-06	4.26e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CD36—atherosclerosis	4.79e-06	4.25e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—INS—atherosclerosis	4.78e-06	4.25e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—atherosclerosis	4.76e-06	4.23e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—atherosclerosis	4.75e-06	4.22e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—LPL—atherosclerosis	4.75e-06	4.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—LPL—atherosclerosis	4.7e-06	4.18e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.7e-06	4.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MTHFR—atherosclerosis	4.65e-06	4.13e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GPX1—atherosclerosis	4.63e-06	4.11e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GPX1—atherosclerosis	4.59e-06	4.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARA—atherosclerosis	4.56e-06	4.05e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MAPK3—atherosclerosis	4.55e-06	4.04e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MTHFR—atherosclerosis	4.53e-06	4.03e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—atherosclerosis	4.52e-06	4.02e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CD36—atherosclerosis	4.51e-06	4.01e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—NFKB1—atherosclerosis	4.47e-06	3.98e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CD36—atherosclerosis	4.47e-06	3.97e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARA—atherosclerosis	4.45e-06	3.95e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.44e-06	3.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AGT—atherosclerosis	4.41e-06	3.92e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFB1—atherosclerosis	4.41e-06	3.92e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK8—atherosclerosis	4.4e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HMOX1—atherosclerosis	4.4e-06	3.91e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—atherosclerosis	4.39e-06	3.9e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ALB—atherosclerosis	4.38e-06	3.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—atherosclerosis	4.37e-06	3.88e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOE—atherosclerosis	4.33e-06	3.84e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AGT—atherosclerosis	4.31e-06	3.83e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CAV1—atherosclerosis	4.29e-06	3.81e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—APOA1—atherosclerosis	4.28e-06	3.8e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.27e-06	3.8e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MTHFR—atherosclerosis	4.24e-06	3.76e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOE—atherosclerosis	4.22e-06	3.75e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—atherosclerosis	4.22e-06	3.75e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOB—atherosclerosis	4.21e-06	3.74e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARA—atherosclerosis	4.19e-06	3.72e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NOS3—atherosclerosis	4.19e-06	3.72e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAV1—atherosclerosis	4.18e-06	3.72e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—APOA1—atherosclerosis	4.17e-06	3.71e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARA—atherosclerosis	4.16e-06	3.69e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—INS—atherosclerosis	4.14e-06	3.68e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.1e-06	3.64e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—atherosclerosis	4.06e-06	3.61e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AGT—atherosclerosis	4.06e-06	3.61e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AGT—atherosclerosis	4.02e-06	3.58e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—atherosclerosis	4.02e-06	3.57e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—LPL—atherosclerosis	4.02e-06	3.57e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—atherosclerosis	4.01e-06	3.56e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOE—atherosclerosis	3.98e-06	3.53e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.95e-06	3.51e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOE—atherosclerosis	3.94e-06	3.5e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAV1—atherosclerosis	3.94e-06	3.5e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—APOA1—atherosclerosis	3.93e-06	3.49e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GPX1—atherosclerosis	3.92e-06	3.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAV1—atherosclerosis	3.91e-06	3.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	3.9e-06	3.47e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—APOA1—atherosclerosis	3.9e-06	3.46e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MAPK3—atherosclerosis	3.84e-06	3.41e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—atherosclerosis	3.83e-06	3.41e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CD36—atherosclerosis	3.82e-06	3.39e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—atherosclerosis	3.81e-06	3.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ALB—atherosclerosis	3.8e-06	3.37e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—atherosclerosis	3.79e-06	3.37e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—atherosclerosis	3.77e-06	3.35e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFB1—atherosclerosis	3.73e-06	3.31e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—INS—atherosclerosis	3.69e-06	3.28e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—atherosclerosis	3.68e-06	3.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NOS3—atherosclerosis	3.63e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.62e-06	3.22e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—INS—atherosclerosis	3.61e-06	3.2e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.59e-06	3.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—atherosclerosis	3.56e-06	3.16e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARA—atherosclerosis	3.55e-06	3.15e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—atherosclerosis	3.5e-06	3.11e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—atherosclerosis	3.46e-06	3.08e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AGT—atherosclerosis	3.44e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—atherosclerosis	3.43e-06	3.05e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—INS—atherosclerosis	3.4e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.39e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ALB—atherosclerosis	3.39e-06	3.01e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOE—atherosclerosis	3.37e-06	2.99e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—INS—atherosclerosis	3.37e-06	2.99e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAV1—atherosclerosis	3.34e-06	2.97e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—APOA1—atherosclerosis	3.33e-06	2.96e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—atherosclerosis	3.32e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—atherosclerosis	3.32e-06	2.95e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ALB—atherosclerosis	3.31e-06	2.94e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOB—atherosclerosis	3.25e-06	2.89e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NOS3—atherosclerosis	3.24e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—atherosclerosis	3.17e-06	2.82e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NOS3—atherosclerosis	3.16e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.16e-06	2.81e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ALB—atherosclerosis	3.12e-06	2.77e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LPL—atherosclerosis	3.1e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ALB—atherosclerosis	3.09e-06	2.74e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—atherosclerosis	3.07e-06	2.72e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.04e-06	2.7e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GPX1—atherosclerosis	3.03e-06	2.69e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NOS3—atherosclerosis	2.98e-06	2.65e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—atherosclerosis	2.96e-06	2.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NOS3—atherosclerosis	2.95e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CD36—atherosclerosis	2.95e-06	2.62e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—atherosclerosis	2.94e-06	2.61e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—atherosclerosis	2.89e-06	2.57e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—INS—atherosclerosis	2.88e-06	2.56e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—atherosclerosis	2.81e-06	2.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.79e-06	2.48e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARA—atherosclerosis	2.74e-06	2.43e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.73e-06	2.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—atherosclerosis	2.7e-06	2.4e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—atherosclerosis	2.69e-06	2.39e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—atherosclerosis	2.67e-06	2.37e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AGT—atherosclerosis	2.65e-06	2.36e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ALB—atherosclerosis	2.64e-06	2.34e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOE—atherosclerosis	2.6e-06	2.31e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—atherosclerosis	2.59e-06	2.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAV1—atherosclerosis	2.58e-06	2.29e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—APOA1—atherosclerosis	2.57e-06	2.28e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NOS3—atherosclerosis	2.52e-06	2.24e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—atherosclerosis	2.44e-06	2.17e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.35e-06	2.09e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.31e-06	2.05e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—atherosclerosis	2.27e-06	2.01e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—INS—atherosclerosis	2.22e-06	1.97e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ALB—atherosclerosis	2.04e-06	1.81e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NOS3—atherosclerosis	1.95e-06	1.73e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—atherosclerosis	1.93e-06	1.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.78e-06	1.58e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—atherosclerosis	1.67e-06	1.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—atherosclerosis	1.49e-06	1.32e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—atherosclerosis	1.45e-06	1.29e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—atherosclerosis	1.37e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—atherosclerosis	1.36e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—atherosclerosis	1.16e-06	1.03e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—atherosclerosis	8.96e-07	7.96e-06	CbGpPWpGaD
